TLCD3A and prostate cancer: In contrast, FAM57A was reported to be a protective gene in prostate cancer in that FAM57A transcript levels were lower in tumorous than in normal prostate tissue, a decrease of FAM57A transcripts correlated with increased prostate cancer grading, and FAM57A silencing weakly enhanced the viability of LnCAP prostate cancer cells [15,16].